Bohai Pharmaceuticals Group (BOPH) Return on Equity ROE from the first quarter 2015 to first quarter 2014 and annually, average high and low, overall ranking from Sep 30 2014 to Sep 30 2013 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Bohai Pharmaceuticals Group, Inc.  (BOPH)

Bohai Pharmaceuticals Group's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Bohai Pharmaceuticals Group in the first quarter 2015?
Bohai Pharmaceuticals Group, Inc. achieved a return on average equity (ROE) of 17.76 % in its first quarter 2015, which is below Bohai Pharmaceuticals Group's average return on equity, which stands at 18.64%.

ROE has advanced compared to 17.62% in the fourth quarter 2014, due to net income growth.

Within the Biotechnology & Pharmaceuticals industry 13 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2014 from 0 to 679.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2014)
I. Quarter		 (Jun 30 2014)
IV. Quarter		 (Mar 31 2014)
III. Quarter		 (Dec 31 2013)
II. Quarter		 (Sep 30 2013)
I. Quarter
Y / Y Equity Change 20.89 % 19.57 % 23.8 % 25.81 % -
Y / Y Net Income Change 15.53 % -10.34 % 24.34 % 14.27 % 26.46 %
Net Income (TTM) in Millions 23 22 22 22 21
Return On Equity (TTM) 17.76 % 17.62 % 18.78 % 19.11 % 19.54 %
BOPH's Total Ranking # 679 # 0 # 0 # 0 # 0
Equity (TTM) in Millions 142 130 126 124 117
Seq. Equity Change 9.23 % 2.46 % 2.21 % 5.68 % 8.04 %
Seq. Net Income Change 141.8 % -1.62 % -34.63 % -25.7 % 87.65 %

Back to BOPH Management Effectiveness >> BOPH's 5 Years Annual ROE >> Compare BOPH ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 14
Sector # 87
Overall # 679

Return On Equity Statistics
High Average Low
19.54 %
18.64 %
17.62 %
(Sep 30 2013)   (Jun 30 2014)





BOPH Annual Return On Equity (Jun 30 2014)
2014		 (Jun 30 2013)
2013		 (Jun 30 2012)
2012

Total Equity in Millions 130 108 87 0 0
Y / Y Equity Change 19.57 % 25.3 % - - -
Net Income in Millions 22 19 10 0 0
Y / Y Net Income Change 14.46 % 98.21 % - - -
Return On Equity 16.89 % 17.64 % 11.15 % - -

Back to BOPH Management Effectiveness >> BOPH's 5 Years Annual ROE >> Compare BOPH ROE to its Competitors




Annual Roe Comment
In 2014 ROE fell to 16.89 %, despite net income growth.


More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
BOPH's' Return on Equity at Yahoo Finance
BOPH's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for BOPH's Competitors
Subscribers only: Roe for Bohai Pharmaceuticals Group's Suppliers
Subscribers only: Return On Equity for BOPH's Customers




Companies with similar Return On Equity at Sep 30 2014, within Healthcare Sector ROE
Zoetis Inc   47.75 %
Idexx Laboratories Inc  46.53 %
Lightwave Logic Inc   45.88 %
Edwards Lifesciences Corporation  45.36 %
Scientific Industries Inc   45.30 %
Astrotech Corp  44.60 %
Aratana Therapeutics, Inc.  43.44 %
Bard C R Inc  43.26 %
Assertio Holdings inc   42.64 %
Agios Pharmaceuticals Inc   42.44 %
China Biologic Products Holdings Inc   40.85 %
Diversicare Healthcare Services Inc   40.76 %
Fonar Corporation  39.82 %
Vbi Vaccines Inc  39.45 %
Tenax Therapeutics Inc   37.14 %
Oncomed Pharmaceuticals Inc  36.99 %
Mettler toledo International Inc   36.21 %
Lannett Company Inc  34.65 %
Portola Pharmaceuticals inc   33.61 %
Insys Therapeutics, Inc.  32.14 %
Celgene Corp  30.93 %
Oramed Pharmaceuticals Inc  30.70 %
Cv Sciences Inc   30.34 %
Remedent Inc   29.06 %
Mylan N v   28.54 %
3m Company  27.99 %
Psychemedics Corporation  27.10 %
Luna Innovations Inc  26.94 %
Enanta Pharmaceuticals Inc  26.81 %
Biogen Inc   26.58 %

Date modified: 2026-09-12T06:21:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.